SARS-CoV-2 (COVID-19) IgG ELISA

Product Name: COVID-19 (SARS-CoV-2) IgG ELISA
Intended Use: For the qualitative determination of IgG class antibodies against SARS-CoV-2 in human serum or plasma (citrate, heparin) to support the diagnosis of COVID-19 disease and constitutes a supplement to direct pathogen detection. Serology can also be used to collect epidemiological information on the prevalence of SARS-CoV-2.
Sample Type: Human serum or Plasma
Specificity: > 99.24%
Regulatory/Restrictions For in-vitro Diagnostic Use Only

Materials Supplied:

– 1X Microtiter plate
– 20X Concentrated wash buffer (60ml)
– Sample diluent (50ml)
– Start reagent (8ml)
– Conjugate (15ml)
– Substrate (15ml)
– Stop solution 0.3M (15ml)
– Positive control (2ml)
– Negative control (2ml)

Storage:

This test kit must be stored at 2 – 8°C upon receipt.
All components are stable until this expiration date.

The qualitative immunoenzymatic determination of specific antibodies is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique. Microtiterplates are coated with specific antigens to bind corresponding antibodies of the sample. After washing the wells to remove all unbound sample material a horseradish peroxidase (HRP) labelled conjugate is added. This conjugate binds to the captured antibodies. In a second washing step unbound conjugate is removed. The immune complex formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate which gives a blue reaction product. The intensity of this product is proportional to the amount of specific antibodies in the sample. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint colour. Absorbance at 450/620 nm is read using an ELISA Microtiterplate reader.

SARS-CoV-2 (COVID-19) IgG ELISA Datasheet

Corona Virus Disease 2019 (COVID-19) is caused by the SARS-associated coronavirus 2 (SARS-CoV-2), which was first identified in a respiratory disease outbreak in Wuhan City, Hubei Province, China. It has since been responsible for a global pandemic. SARS-CoV-2 is a single-stranded RNA virus with positive polarity and belongs to the genus of beta-coronaviruses, which also includes SARS CoV (2003) and MERS CoV (2012). Like all other corona viruses, the genome of SARS CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein and the nucleocapsid protein.

ELISA kits for COVID-19 diagnostics

COVID-19 positive patients display a variety of symptoms with a large range of severity. Current research guidance suggests the length of time from initial infection with SARS-CoV-2 and appearance of first symptoms can be up to 14 days. RT-qPCR tests performed in hospital to confirm diagnosis in acute patients. This type of test examines the genetic material of the virus and give a positive result only if the virus is still present at a critical level. The tests are unable to identify individuals who have recovered. The GA CoV-2 ELISA kits are serological tests that identify virus-specific antibodies in patients both during and post infection. Understanding the level of population exposure to SARS-CoV-2 and the number of recovered patients is key to a resilient pandemic response. Our simple GA CoV-2 Two Step ELISA confirms active cases and can indicate the level of immune protection following recovery by specifically identifying the IgG response to N-, S1- and S2- proteins are determined using GA CoV-2 IgG+ EIA  confirmatory test.